GlassScriptPhysician profile
Edward Y Chay
NPI 1851666143
$3,491.89
in general payments reported to CMS, 2019-2025
24 companies · $243 in 2025
The $243 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $114 · 2021: $235 · 2022: $946 · 2023: $914 · 2024: $556 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,713.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $927.38 | 2022-2025 | Lumigan, Vuity, Xen Glaucoma Treatment System |
| Allergan, INC. | $464.27 | 2019-2022 | |
| Alcon Vision LLC | $302.44 | 2019-2025 | Tryptyr, Clareon Panoptix Pro, Clareon |
| Rxsight INC | $240.57 | 2022-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Tarsus Pharmaceuticals, INC. | $195.35 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $169.21 | 2019-2021 | |
| Oyster Point Pharma, INC. | $163.08 | 2022-2024 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $159.13 | 2019-2023 | Cequa |
| Notal Vision, INC. | $139.90 | 2022 | |
| Dompe US, INC. | $124.74 | 2023 | Oxervate |
| Bausch & Lomb Americas INC. | $112.19 | 2022-2024 | Envista Mx60 Iol, Stellaris Elite, Trulign Iol |
| Aerie Pharmaceuticals, INC. | $90.00 | 2019 | |
| Rayner Intraocular Lenses Limited | $61.50 | 2023 | Omidria, Rayone Emv, Rayone Aspheric |
| Harrow Eye, LLC | $54.50 | 2024-2025 | Vevye |
| Amgen INC. | $51.47 | 2025 | Tepezza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $41.04 | 2019-2023 | |
| Sight Sciences, INC. | $40.21 | 2023-2024 | Omni Surgical System, Sion Surgical Instrument |
| Eyevance Pharmaceuticals LLC | $34.85 | 2020 | |
| Mallinckrodt Hospital Products INC. | $29.61 | 2023 | Acthar |
| Thea Pharma INC. | $23.28 | 2023 | Iyuzeh |
| Horizon Therapeutics Plc | $22.74 | 2019 | |
| Shire North American Group INC | $15.79 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.38 | 2021 | |
| Biotissue Holdings INC. | $14.26 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Chay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.